Legal Representation
Attorney
Douglas T. Johnson
USPTO Deadlines
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 4, 2025 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Dec 19, 2024 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Dec 16, 2024 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Oct 7, 2024 | MAB1 | E | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | Loading... |
| Oct 7, 2024 | ABN1 | O | ABANDONMENT - EXPRESS MAILED | Loading... |
| Sep 30, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 30, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 30, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 23, 2024 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Mar 29, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Mar 29, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Mar 10, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Mar 9, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 6, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 21, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Jul 17, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 14, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Viral systems, gene therapy systems, nucleic acid delivery systems, namely, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis products and other pharmaceutical products for use in nucleic acid-based therapy, gene therapy and cell therapy
Class 042
Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; research and product development in the field of pharmaceutics
Class 044
Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics
Classification
International Classes
005
042
044